Seractide acetate
As of the edition of 20 October 2026, Seractide acetate is a protein: withdrawn from the market in 2017; acts on MC2R; no US protection is listed.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2017
- Kind
- Protein
- Brand name
- Acthar Gel-Synthetic
- First approved
- 1 January 1982 (US)
- Approvals on record
- 2 in 1 region
- Holder of the most recent approval
- ARMOUR PHARMACEUTICAL CO
- Withdrawn from market
- 1 January 2017 (in some regions)
US protection
No US protection is listed.
The FDA registers list no drug-substance patent or exclusivity that counts for this drug.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| MC2R | Adrenocorticotropic hormone receptor | Q01718 |